SELGIAN 40 kg, Film coated tablets

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

유효 성분:

Selegiline hydrochloride

제공처:

Ceva Animal Health Limited

ATC 코드:

QN06A

INN (국제 이름):

Selegiline hydrochloride

복용량:

16.74 mg/tablet

약제 형태:

Film-coated tablet

처방전 유형:

POM: Prescription Only Medicine as defined in relevant national legislation

치료 그룹:

Dogs

치료 영역:

ANTIDEPRESSANTS

치료 징후:

Neurological Preparations

승인 상태:

Authorised

승인 날짜:

2002-11-22

제품 특성 요약

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
SELGIAN 40kg, Film coated tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a 1020 mg tablet
Active substance:
Selegiline (as hydrochloride)
16.74 mg
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Film-coated tablet.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs (from 26 kg to 86 kg).
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
-
Treatment of behavioural disorders of purely emotional origin:
depression, dysthymia, anxiety.
-
In combination with behaviour therapy, treatment of disorders of
emotional origin found in
hypersensibility/hyperactivity, separation anxiety, deprivation
syndrome and generalised phobia.
4.3 CONTRAINDICATIONS
Owing to its MAOI properties, selegiline may act on prolactin
secretion. For want of specific studies, the product
should not be administered to pregnant and lactating bitches.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
The use of a dosage less than the recommended dosage may result in
exacerbation of the dog’s aggressiveness in case
of latent hierarchy conflict. If no clinical improvement is observed
after 2 months, it is useless to continue the
treatment.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_8_
_/_
_1_
_1_
_/_
_2_
_0_
_1_
_4_
_C_
_R_
_N_
_ _
_7_
_0_
_1_
_9_
_2_
_4_
_4_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Emotional disorders can m